The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer
Open accessAbstract
Purpose: This phase III, multicenter, randomized, placebo-controlled trial assessed the efficacy and safety of sorafenib, an oral multikinase inhibitor, in combination with carboplatin and paclitaxel in chemotherapy-naïve patients with unresectable stage IIIB or IV non–small-cell lung cancer (NSCLC). Patients and Methods: Nine hundred twenty-six patients were randomly assigned to receive up to six 21-day cycles of carboplatin area under the curve 6 and paclitaxel 200 mg/m 2 (CP) on day 1, followed by either sorafenib 400 mg twice a day (n = 464, arm A) or placebo (n = 462, arm B) on days 2 to 19. The maintenance phase after CP consisted of sorafenib 400 mg or placebo twice a day. The primary end point was overall survival (OS); secondary end points included progression-free survival and tumor response. Results: Overall demographics were balanced between arms; 223 patients (24%) had squamous cell histology. On the basis of a planned interim analysis, median OS was 10.7 months in arm A and 10.6 months in arm B (hazard ratio [HR] = 1.15; 95% CI, 0.94 to 1.41; P = .915). The study was terminated after the interim analysis concluded that the study was highly unlikely to meet its primary end point. A prespecified exploratory analysis revealed that patients with squamous cell histology had greater mortality in arm A than in arm B (HR = 1.85; 95% CI, 1.22 to 2.81). Main grade 3 or 4 sorafenib-related toxicities included rash (8.4%), hand-foot skin reaction (7.8%), and diarrhea (3.5%). Conclusion: No clinical benefit was observed from adding sorafenib to CP chemotherapy as first-line treatment for NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Delbaldo, C., Michiels, S., Rolland, E., Syz, N., Soria, J., Chevalier, T. L., & Pignon, J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004569.pub3 · Cited by 43
RetractedNew Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Self-citationJohnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Self-citationHerbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
Self-citationReck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,505
Self-citationHerbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490
Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., & Lynch, M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0013 · Cited by 1,459
Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W., Smith, T. J., Baker Jr, S., Olak, J., Stover, D., Strawn, J. R., Turrisi, A. T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,413
Pirker, R., Pereira, J. R., Szczesna, A., von Pawel, J., Krzakowski, M., Ramlau, R., Vynnychenko, I., Park, K., Yu, C.-T., Ganul, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60569-9 · Cited by 1,351
Self-citationKelly, K., Crowley, J., Bunn, P. A., Presant, C. A., Grevstad, P. K., Moinpour, C. M., Ramsey, S. D., Wozniak, A. J., Weiss, G. R., Moore, D. F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3210 · Cited by 1,123
Fossella, F., Pereira, J. R., von Pawel, J., Pluzanska, A., Gorbounova, V., Kaukel, E., Mattson, K. V., Ramlau, R., Szczęsna, A., Fidias, P., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.046 · Cited by 939
Self-citationScagliotti, G. V., De Marinis, F., Rinaldi, M., Crinò, L., Gridelli, C., Ricci, S., Matano, E., Boni, C., Marangolo, M., Failla, G., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.068 · Cited by 889
Self-citationGatzemeier, U., Pluzanska, A., Szczesna, A., Kaukel, E., Roubec, J., De Rosa, F., Milanowski, J., Karnicka-Mlodkowski, H., Pesek, M., Serwatowski, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1474 · Cited by 881
Self-citationStrumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872
Hauschild, A., Agarwala, S. S., Trefzer, U., Hogg, D., Robert, C., Hersey, P., Eggermont, A., Grabbe, S., Gonzalez, R., Gille, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7636 · Cited by 548
Evans, W. K. (. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.08.002 · Cited by 405
Breathnach, O. S., Freidlin, B., Conley, B., Green, M. R., Johnson, D. H., Gandara, D. R., O’Connell, M., Shepherd, F. A., & Johnson, B. E. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1734 · Cited by 354
Clark, J. W., Eder, J. P., Ryan, D., Lathia, C., & Lenz, H.-J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2658 · Cited by 342
Moore, M., Hirte, H. W., Siu, L., Oza, A., Hotte, S. J., Petrenciuc, O., Cihon, F., Lathia, C., & Schwartz, B. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi310 · Cited by 305
Self-citationDowlati, A., Gray, R., Sandler, A. B., Schiller, J. H., & Johnson, D. H. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1154 · Cited by 263
Blumenschein, G. R., Gatzemeier, U., Fossella, F., Stewart, D. J., Cupit, L., Cihon, F., O'Leary, J., & Reck, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.0541 · Cited by 205
Self-citationNew molecularly targeted therapies for lung cancer
Sun, S., Schiller, J. H., Spinola, M., & Minna, J. D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31809 · Cited by 201
Dermatologic symptoms associated with the multikinase inhibitor sorafenib
Robert, C., Mateus, C., Spatz, A., Wechsler, J., & Escudier, B. J. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.06.034 · Cited by 154
Flaherty, K. T., Schiller, J. H., Schuchter, L. M., Liu, G., Tuveson, D. A., Redlinger, M., Lathia, C. D., Xia, C., Petrenciuc, O., Hingorani, S. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4123 · Cited by 148
Khuri, F. R., Rigas, J. R., Figlin, R. A., Gralla, R. J., Shin, D. M., Munden, R. F., Fox, N., Huyghe, M. R., Kean, Y., Reich, S. D., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2626 · Cited by 121
Laurie, S. A., Gauthier, I. C., Arnold, A., Shepherd, F. A., Ellis, P. M., Chen, E. X., Goss, G. D., Powers, J., Walsh, W., Tu, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4741 · Cited by 119
Kim, E. S., Kies, M. S., Fossella, F. V., Glisson, B. S., Zaknoen, S. L., Statkevich, P., Munden, R. F., Summey, C., Pisters, K. M. W., Papadimitrakopoulou, V., et al. (2005) · Cancer · doi:10.1002/cncr.21188 · Cited by 110
Phase II Multicenter Study of Arsenic Trioxide in Patients With Myelodysplastic Syndromes
Schiller, G. J., Slack, J. L., Hainsworth, J. D., Mason, J. R., Saleh, M. N., Rizzieri, D. A., Douer, D., & List, A. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7903 · Cited by 106
Blumenschein, G. R., Khuri, F. R., von Pawel, J., Gatzemeier, U., Miller, W. H., Jotte, R. M., Treut, J. H. L., Sun, S.-L., Zhang, J. K., Dziewanowska, Z. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2689 · Cited by 95
Bonnesen, B., Pappot, H., Holmstav, J., & Skov, B. G. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.02.013 · Cited by 75
Miller, V. A., Johnson, D. H., Krug, L. M., Pizzo, B., Tyson, L. B., Perez, W., Krozely, P., Sandler, A. B., Carbone, D. P., Heelan, R. T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.008 · Cited by 64
Patnaik, A., Wood, D. L., Tolcher, A. W., Hamilton, M., Kreisberg, J. I., Hammond, L. A., Schwartz, G. H., Beeram, M., Hidalgo, M. M., Mita, M. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1886 · Cited by 26
Blumenschein, G. R., Ludwig, C., Thomas, G., Tan, E., Fanucchi, M., Santoro, A., Crawford, J., Breton, J. L., O’Brien, M., & Khuri, F. R. (2005) · Lung Cancer · doi:10.1016/s0169-5002(05)80215-6 · Cited by 24
Davidoff, A. M., Ng, C. Y., Zhang, Y., Streck, C. J., Mabry, S. J., Barton, S. H., Baudino, T. A., Zhou, J., Kerbel, R. S., Vanin, E. F., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.09.014 · Cited by 20
Cited by
Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70586-2 · Cited by 951
Self-citationPlatinum-based drugs: past, present and future
Dilruba, S., & Kalayda, G. V. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2976-z · Cited by 906
Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 756
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.05.01 · Cited by 716
Management of non-small-cell lung cancer: recent developments
Reck, M., Heigener, D. F., Mok, T., Soria, J.-C., & Rabe, K. F. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61502-0 · Cited by 714
Self-citation
Metadata
- Authors
- Scagliotti, G., Novello, S., von Pawel, J., Reck, M., Pereira, J. R., Thomas, M., Abrão Miziara, J. E., Balint, B., De Marinis, F., Keller, A., Arén, O., Csollak, M., Albert, I., Barrios, C. H., Grossi, F., Krzakowski, M., Cupit, L., Cihon, F., DiMatteo, S., & Hanna, N.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-04-10
- Volume
- 28
- Issue
- 11
- Pages
- 1835-1842
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2159370421
- Cited by
- 447
- References
- 41
- FWCI
- 55.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.